This formulation was efficiently internalized by HER-2-overexpressing breast cancer cells (SK-BR3 cells) and was barely taken up by HER-2-negative cells, also exerting an anticancer activity that was slightly higher than free paclitaxel. Here, ERBB2 is linked to breast cancer.